ERBB2 and adenocarcinoma: Therefore, this study aims to evaluate the cost-effectiveness of CAD-CHM compared with PLA-CHM as a first-line treatment for HER2-negative advanced G/GEJ adenocarcinoma from the perspective of the Chinese healthcare system.